Inhibition of the ATP synthase eliminates the intrinsic resistance of Staphylococcus aureus towards polymyxins

mBio

Volumn 8, Issue 5, 2017, Pages

  Vestergaard, Martin ^a   Nøhr Meldgaard, Katrine ^a   Bojer, Martin Saxtorph ^a   Krogsgård Nielsen, Christina ^b   Meyer, Rikke Louise ^b   Slavetinsky, Christoph ^c   Peschel, Andreas ^c   Ingmer, Hanne ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Antimicrobial peptides; ATP synthase; AtpA; Intrinsic resistance; Oligomycin A; Polymyxin; Staphylococcus aureus

Indexed keywords

CIPROFLOXACIN; COLISTIN; DAPTOMYCIN; GALLIDERMIN; GENTAMICIN; LINEZOLID; NISIN; OLIGOMYCIN; OXACILLIN; POLYMYXIN B; POLYMYXIN DERIVATIVE; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; VANCOMYCIN; ANTIINFECTIVE AGENT; POLYMYXIN; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATASE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; ATPA GENE; ATPB GENE; ATPG GENE; ATPH GENE; BACTERIAL METABOLISM; DRUG ACTIVITY; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; GENE; GENE INACTIVATION; GENETIC CODE; GRAR GENE; GRAS GENE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; VRAF GENE; VRAG GENE; WHOLE GENOME SEQUENCING; ANTAGONISTS AND INHIBITORS; DRUG EFFECT; ENZYMOLOGY; GENE LIBRARY; GENETICS; MICROBIAL SENSITIVITY TEST; MUTATION;

ANTI-BACTERIAL AGENTS; ATP SYNTHETASE COMPLEXES; COLISTIN; DAPTOMYCIN; DRUG RESISTANCE, BACTERIAL; GENE LIBRARY; MICROBIAL SENSITIVITY TESTS; MUTATION; NISIN; POLYMYXINS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 85033374201     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.01114-17     Document Type: Article

References (50)

1. Zavascki AP, Goldani LZ, Li J, Nation RL. 2007. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J Antimicrob Chemother 60:1206–1215. https://doi.org/10.1093/jac/dkm357.
2. Hermsen ED, Sullivan CJ, Rotschafer JC. 2003. Polymyxins: pharmacology, pharmacokinetics, pharmacodynamics, and clinical applications. Infect Dis Clin North Am 17:545–562. https://doi.org/10.1016/S0891 -5520(03)00058-8.
3. Vaara M. 1992. Agents that increase the permeability of the outer membrane. Microbiol Rev 56:395–411.
4. Peschel A, Sahl HG. 2006. The co-evolution of host cationic antimicrobial peptides and microbial resistance. Nat Rev Microbiol 4:529–536. https://doi.org/10.1038/nrmicro1441.
5. Sabath LD, Garner C, Wilcox C, Finland M. 1976. Susceptibility of Staphylococcus aureus and Staphylococcus epidermidis to 65 antibiotics. Antimicrob Agents Chemother 9:962–969. https://doi.org/10.1128/AAC.9.6.962.
6. Joo HS, Otto M. 2015. Mechanisms of resistance to antimicrobial peptides in staphylococci. Biochim Biophys Acta 1848:3055–3061. https://doi.org/10.1016/j.bbamem.2015.02.009.
7. Jin T, Bokarewa M, Foster T, Mitchell J, Higgins J, Tarkowski A. 2004. Staphylococcus aureus resists human defensins by production of staphylokinase, a novel bacterial evasion mechanism. J Immunol 172: 1169–1176. https://doi.org/10.4049/jimmunol.172.2.1169.
8. Kupferwasser LI, Skurray RA, Brown MH, Firth N, Yeaman MR, Bayer AS. 1999. Plasmid-mediated resistance to thrombin-induced platelet micro-bicidal protein in staphylococci: role of the qacA locus. Antimicrob Agents Chemother 43:2395–2399.
9. Peschel A, Otto M, Jack RW, Kalbacher H, Jung G, Götz F. 1999. Inactivation of the dlt operon in Staphylococcus aureus confers sensitivity to defensins, protegrins, and other antimicrobial peptides. J Biol Chem 274:8405–8410. https://doi.org/10.1074/jbc.274.13.8405.
10. L-lysine. J Exp Med 193: 1067–1076. https://doi.org/10.1084/jem.193.9.1067.
11. Falord M, Karimova G, Hiron A, Msadek T. 2012. GraXSR proteins interact with the VraFG ABC transporter to form a five-component system required for cationic antimicrobial peptide sensing and resistance in Staphylococcus aureus. Antimicrob Agents Chemother 56:1047–1058. https://doi.org/10.1128/AAC.05054-11.
12. Meehl M, Herbert S, Götz F, Cheung A. 2007. Interaction of the GraRS two-component system with the VraFG ABC transporter to support vancomycin-intermediate resistance in Staphylococcus aureus. Antimicrob Agents Chemother 51:2679–2689. https://doi.org/10.1128/AAC.00209-07.
13. Lowy FD. 1998. Staphylococcus aureus infections. N Engl J Med 339: 520–532. https://doi.org/10.1056/NEJM199808203390806.
14. Butler MS, Blaskovich MA, Cooper MA. 2013. Antibiotics in the clinical pipeline in 2013. J Antibiot 66:571–591. https://doi.org/10.1038/ja.2013.86.
15. Fey PD, Endres JL, Yajjala VK, Widhelm TJ, Boissy RJ, Bose JL, Bayles KW. 2013. A genetic resource for rapid and comprehensive phenotype screening of nonessential Staphylococcus aureus genes. mBio 4:e00537 -12. https://doi.org/10.1128/mBio.00537-12.
16. Yoshida T, Hiramatsu K. 1993. Potent in vitro bactericidal activity of polymyxin B against methicillin-resistant Staphylococcus aureus (MRSA). Microbiol Immunol 37:853–859. https://doi.org/10.1111/j.1348-0421.1993.tb01716.x.
17. + uptake protein, TrkA, is required for serum, protamine, and polymyxin B resistance in Vibrio vulnificus. Infect Immun 72:629–636. https://doi.org/10.1128/IAI.72.2.629-636.2004.
18. Walker JE. 2013. The ATP synthase: the understood, the uncertain and the unknown. Biochem Soc Trans 41:1–16. https://doi.org/10.1042/BST20110773.
19. Salcedo G, Cano-Sánchez P, de Gómez-Puyou MT, Velázquez-Campoy A, García-Hernández E. 2014. Isolated noncatalytic and catalytic subunits of F1-ATPase exhibit similar, albeit not identical, energetic strategies for recognizing adenosine nucleotides. Biochim Biophys Acta 1837:44–50. https://doi.org/10.1016/j.bbabio.2013.08.005.
20. Liu A, Tran L, Becket E, Lee K, Chinn L, Park E, Tran K, Miller JH. 2010. Antibiotic sensitivity profiles determined with an Escherichia coli gene knockout collection: generating an antibiotic bar code. Antimicrob Agents Chemother 54:1393–1403. https://doi.org/10.1128/AAC.00906-09.
21. McCoy AJ, Liu H, Falla TJ, Gunn JS. 2001. Identification of Proteus mirabilis mutants with increased sensitivity to antimicrobial peptides. Antimicrob Agents Chemother 45:2030–2037. https://doi.org/10.1128/AAC.45.7.2030-2037.2001.
22. Shen CJ, Kuo TY, Lin CC, Chow LP, Chen WJ. 2010. Proteomic identification of membrane proteins regulating antimicrobial peptide resistance in Vibrio parahaemolyticus. J Appl Microbiol 108:1398–1407. https://doi.org/10.1111/j.1365-2672.2009.04544.x.
23. Falagas ME, Kasiakou SK. 2005. Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin Infect Dis 40:1333–1341. https://doi.org/10.1086/429323.
24. CLSI. 2011. Performance standards for antimicrobial susceptibility testing: twenty-first informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
25. Andrä J, Goldmann T, Ernst CM, Peschel A, Gutsmann T. 2011. Multiple peptide resistance factor (MprF)-mediated resistance of Staphylococcus aureus against antimicrobial peptides coincides with a modulated peptide interaction with artificial membranes comprising lysyl-phosphatidylglycerol. J Biol Chem 286:18692–18700. https://doi.org/10.1074/jbc.M111.226886.
26. Yeaman MR, Yount NY. 2003. Mechanisms of antimicrobial peptide action and resistance. Pharmacol Rev 55:27–55. https://doi.org/10.1124/pr.55.1.2.
27. Taber HW, Mueller JP, Miller PF, Arrow AS. 1987. Bacterial uptake of aminoglycoside antibiotics. Microbiol Rev 51:439–457.
28. o -ATP synthase mutant devoid of oxidative phosphorylation. Biochim Biophys Acta 1817:370–380. https://doi.org/10.1016/j.bbabio.2011.10.006.
29. Haaber J, Friberg C, McCreary M, Lin R, Cohen SN, Ingmer H. 2015. Reversible antibiotic tolerance induced in Staphylococcus aureus by concurrent drug exposure. mBio 6:e02268-14. https://doi.org/10.1128/mBio.02268-14.
30. Ouhara K, Komatsuzawa H, Kawai T, Nishi H, Fujiwara T, Fujiue Y, Kuwabara M, Sayama K, Hashimoto K, Sugai M. 2008. Increased resistance to cationic antimicrobial peptide LL-37 in methicillin-resistant strains of Staphylococcus aureus. J Antimicrob Chemother 61: 1266–1269. https://doi.org/10.1093/jac/dkn106.
31. Shireen T, Singh M, Das T, Mukhopadhyay K. 2013. Differential adaptive responses of Staphylococcus aureus to in vitro selection with different antimicrobial peptides. Antimicrob Agents Chemother 57:5134–5137. https://doi.org/10.1128/AAC.00780-13.
32. Hong S, Pedersen PL. 2008. ATP synthase and the actions of inhibitors utilized to study its roles in human health, disease, and other scientific areas. Microbiol Mol Biol Rev 72:590–641. https://doi.org/10.1128/MMBR.00016-08.
33. Lee SH, Wang H, Labroli M, Koseoglu S, Zuck P, Mayhood T, Gill C, Mann P, Sher X, Ha S, Yang SW, Mandal M, Yang C, Liang L, Tan Z, Tawa P, Hou Y, Kuvelkar R, DeVito K, Wen X, Xiao J, Batchlett M, Balibar CJ, Liu J, Xiao J, Murgolo N, Garlisi CG, Sheth PR, Flattery A, Su J, Tan C, Roemer T. 2016. TarO-specific inhibitors of wall teichoic acid biosynthesis restore α-lactam efficacy against methicillin-resistant staphylococci. Sci Transl Med 8:329ra32. https://doi.org/10.1126/scitranslmed.aad7364.
34. Dymek A, Armada A, Handzlik J, Viveiros M, Spengler G, Molnar J, Kieć-Kononowicz K, Amaral L. 2012. The activity of 16 new hydantoin compounds on the intrinsic and overexpressed efflux pump system of Staphylococcus aureus. In Vivo 26:223–229.
35. Kumar A, Khan IA, Koul S, Koul JL, Taneja SC, Ali I, Ali F, Sharma S, Mirza ZM, Kumar M, Sangwan PL, Gupta P, Thota N, Qazi GN. 2008. Novel structural analogues of piperine as inhibitors of the NorA efflux pump of Staphylococcus aureus. J Antimicrob Chemother 61:1270–1276. https://doi.org/10.1093/jac/dkn088.
36. Gibbons S, Oluwatuyi M, Kaatz GW. 2003. A novel inhibitor of multidrug efflux pumps in Staphylococcus aureus. J Antimicrob Chemother 51: 13–17. https://doi.org/10.1093/jac/dkg044.
37. Andries K, Verhasselt P, Guillemont J, Göhlmann HW, Neefs JM, Winkler H, Van Gestel J, Timmerman P, Zhu M, Lee E, Williams P, de Chaffoy D, Huitric E, Hoffner S, Cambau E, Truffot-Pernot C, Lounis N, Jarlier V. 2005. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307:223–227. https://doi.org/10.1126/science.1106753.
38. Balemans W, Vranckx L, Lounis N, Pop O, Guillemont J, Vergauwen K, Mol S, Gilissen R, Motte M, Lançois D, De Bolle M, Bonroy K, Lill H, Andries K, Bald D, Koul A. 2012. Novel antibiotics targeting respiratory ATP synthesis in Gram-positive pathogenic bacteria. Antimicrob Agents Chemother 56:4131–4139. https://doi.org/10.1128/AAC.00273-12.
39. Alteri CJ, Lindner JR, Reiss DJ, Smith SN, Mobley HL. 2011. The broadly conserved regulator PhoP links pathogen virulence and membrane potential in Escherichia coli. Mol Microbiol 82:145–163. https://doi.org/10.1111/j.1365-2958.2011.07804.x.
40. Kislak JW. 1972. The susceptibility of Bacteroides fragilis to 24 antibiotics. J Infect Dis 125:295–299. https://doi.org/10.1093/infdis/125.3.295.
41. Watt B. 1979. Antibiotic susceptibility of anaerobic bacteria. J Infect 1:39–48. https://doi.org/10.1016/S0163-4453(79)80042-0.
42. Hill D, Rose B, Pajkos A, Robinson M, Bye P, Bell S, Elkins M, Thompson B, MacLeod C, Aaron SD, Harbour C. 2005. Antibiotic susceptibilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions. J Clin Microbiol 43:5085–5090. https://doi.org/10.1128/JCM.43.10.5085-5090.2005.
43. Brochmann RP, Toft A, Ciofu O, Briales A, Kolpen M, Hempel C, Bjarnsholt T, Høiby N, Jensen PØ. 2014. Bactericidal effect of colistin on planktonic Pseudomonas aeruginosa is independent of hydroxyl radical formation. Int J Antimicrob Agents 43:140–147. https://doi.org/10.1016/j.ijantimicag.2013.10.015.
44. Duetz WA, Rüedi L, Hermann R, O’Connor K, Büchs J, Witholt B. 2000. Methods for intense aeration, growth, storage, and replication of bacterial strains in microtiter plates. Appl Environ Microbiol 66:2641–2646. https://doi.org/10.1128/AEM.66.6.2641-2646.2000.
45. Proctor RA, Von Eiff C, Kahl BC, Becker K, McNamara P, Herrmann M, Peters G. 2006. Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections. Nat Rev Microbiol 4:295–305. https://doi.org/10.1038/nrmicro1384.
46. Geiger T, Francois P, Liebeke M, Fraunholz M, Goerke C, Krismer B, Schrenzel J, Lalk M, Wolz C. 2012. The stringent response of Staphylococcus aureus and its impact on survival after phagocytosis through the induction of intracellular PSMs expression. PLoS Pathog 8:e1003016. https://doi.org/10.1371/journal.ppat.1003016.
47. Monk IR, Tree JJ, Howden BP, Stinear TP, Foster TJ. 2015. Complete bypass of restriction systems for major Staphylococcus aureus lineages. mBio 6:e00308-15. https://doi.org/10.1128/mBio.00308-15.
48. D-alanylation are common phenotypes among daptomycin-resistant methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates. PLoS One 8:e67398. https://doi.org/10.1371/journal.pone.0067398.
49. Bligh EG, Dyer WJ. 1959. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37:911–917. https://doi.org/10.1139/o59-099.
50. Slavetinsky CJ, Peschel A, Ernst CM. 2012. Alanyl-phosphatidylglycerol and lysyl-phosphatidylglycerol are translocated by the same MprF flip-pases and have similar capacities to protect against the antibiotic daptomycin in Staphylococcus aureus. Antimicrob Agents Chemother 56: 3492–3497. https://doi.org/10.1128/AAC.00370-12.